Cargando…
Use of Clopidogrel and Proton Pump Inhibitors Alone or in Combinations in Persons with Diabetes in Denmark; Potential for CYP2C19 Genotype-Guided Drug Therapy
Background: Clopidogrel and proton pump inhibitors (PPIs) are among the most used drugs in Denmark for which there exists pharmacogenomics (PGx)-based dosing guidelines and FDA annotations. In this study, we further scrutinized the use of clopidogrel and PPIs when prescriptions were redeemed from Da...
Autores principales: | Westergaard, Niels, Tarnow, Lise, Vermehren, Charlotte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916548/ https://www.ncbi.nlm.nih.gov/pubmed/33578832 http://dx.doi.org/10.3390/metabo11020096 |
Ejemplares similares
-
Comparison of Multidrug Use in the General Population and among Persons with Diabetes in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines
por: Westergaard, Niels, et al.
Publicado: (2021) -
Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug–Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients
por: Westergaard, Niels, et al.
Publicado: (2020) -
Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs
por: Douglas, Ian J, et al.
Publicado: (2012) -
Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidence
por: Mistry, Suresh D., et al.
Publicado: (2011) -
Drug Use among Nursing Home Residents in Denmark for Drugs Having Pharmacogenomics Based (PGx) Dosing Guidelines: Potential for Preemptive PGx Testing
por: Vermehren, Charlotte, et al.
Publicado: (2020)